ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "aTyr Pharma, Inc." (LIFE) Report Updated: Oct 15, 2017 | Print This Page

Get more stock ratings by Louis Navellier

"aTyr Pharma, Inc." (LIFE)

Rating: Buy Volatility: Aggressive
Total Grade: B Industry: Biotechnology
Competitors: BIOP,CYAD,IMMU,ABUS

Stock Analysis

Rating: Monthly View

A
B
C
D
F
October November December January February March April May June July August September

Rating: Weekly View

This Week: B down upgrade
Last Week: C same no change
Two Weeks Ago: C up upgrade
service keys

"aTyr Pharma, Inc."© quotemedia

Company Profile

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and clinical development of Physiocrine-based therapeutics for patients suffering from severe and rare diseases. The company develops Resolaris, which is in Phase Ib/II clinical trials for treating adult patients with facioscapulohumeral muscular dystrophy (FSHD), a rare genetic myopathy with an immune component; patients with early onset FSHD; and adult patients with limb-girdle muscular dystrophy 2B or FSHD. In addition, the company is developing iMod.Fc, a preclinical immuno-modulatory domain program. The company was founded in 2005 and is headquartered in San Diego, California.